Resveratrol inhibits nonalcoholic fatty liver disease in rats
Luis Bujanda*1, Elizabeth Hijona1, Mikel Larzabal2, Marta Beraza1, Pablo Aldazabal3, Nerea García-Urkia3, Cristina Sarasqueta4, Angel Cosme1, Belen Irastorza5, Alberto González6 and Juan I Arenas Jr1

Address: 1Department of Gastroenterology, University of Country Basque, Donostia Hospital, Centro de Investigación Biomédica en Enfermedades Hepáticas y Digestivas (CIBERehd), San Sebastián, Spain, 2Department of Pathology, Donostia Hospital, San Sebastián, Spain, 3Department of Experimental Surgery, Donostia Hospital, San Sebastián, Spain, 4Department of Epidemiology, Donostia Hospital, San Sebastián, Spain, 5Department of Pharmacology, Donostia Hospital, San Sebastián, Spain and 6Department of Microbiology, Donostia Hospital, San Sebastián, Spain

Email: Luis Bujanda* - medik@telefonica.net; Elizabeth Hijona - castro@medynet.com; Mikel Larzabal - castro@medynet.com; Marta Beraza - medik@telefonica.net; Pablo Aldazabal - medik@telefonica.net; Nerea García-Urkia - medik@telefonica.net; Cristina Sarasqueta - medik@telefonica.net; Angel Cosme - medik@telefonica.net; Belen Irastorza - medik@telefonica.net; Alberto González - castro@medynet.com; Juan I Arenas - castro@medynet.com

* Corresponding author

Abstract

Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress.

Methods: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured.

Results: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α: 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA: 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05).

Conclusion: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities.
Background
Nonalcoholic fatty liver disease (NAFLD) is characterized by histological changes similar to those seen in subjects with alcoholic hepatitis but in whom alcohol intake is absent or poorly significant. Factors promoting NAFLD development include obesity and diabetes. From 69% to 100% of patients with NAFLD are obese [1]. NAFLD prevalence in severe obesity is greater than 30% [2,3]. Because of all these reasons, it is important to have animal models that allow us to study the effect of different substances on NAFLD.

Polyphenols have a variety of biological functions, including antioxidant, anti-inflammatory, and anticancer effects [4]. Resveratrol is a phytoalexin polyphenolic compound occurring in various plants, including grapes, berries, and peanuts. Multiple lines of compelling evidence suggest its beneficial effects on neurological, hepatic, and cardiovascular systems. The potential mechanisms responsible for its biological activities include downregulation of the inflammatory response through inhibition of the synthesis and release of pro-inflammatory mediators, modification of eicosanoid synthesis, inhibition of Kupffer cells and adhesion molecules, inhibition of inducible nitric oxide synthase and cyclooxygenase-2 (COX-2) via its inhibitory effects on nuclear factor (kappa)B (NF-kB) or the activator protein-1 (AP-1) (5,6). In our previous studies, resveratrol was seen to decrease the liver lesions and transaminase elevations caused by alcohol in mice [7].

Our purpose now was to investigate first whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and second, whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production and oxidative stress.

Methods
Animals and diets
Wistar CRL: Wi (Han) male rats (Charles River) weighing approximately 225 g were used. All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US Public Health Service. Animals were kept on a regular 12-hour light period at a controlled temperature (25 ± 2°C). The modified diet (high carbohydrate-fat free) consisted of carbohydrates (80%, as starch), protein (16%, as casein), and vitamins and minerals (4%)(PANLAB, Barcelona, Spain). The standard diet consisted of a balanced diet containing carbohydrates (51%), protein (16%), vitamins and minerals (4%), and lipids (3%). The standard diet contained 2.9 kcal/g and the modified diet 3.58 kcal/g. The model was based on the model reported by Delzenne in 1997 [8].

Experimental procedures
Rats were distributed into three groups: control, steatosis and resveratrol. The control group was given free access to feed and drink. The control group was fed a standard diet. The steatosis and resveratrol groups were given free access to feed and water 4 days per week, and were fasted for the remaining 3 days (access to water was only allowed). Feed consisted of a modified diet. During the dietary restriction cycles, steatosis and resveratrol groups were fed a modified diet (Figure 1). Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route through an orogastric catheter. Resveratrol was diluted in 1 mL of water. Resveratrol was obtained from SIGMA Chemical, (Pool, Dorset, UK).

All rats were killed after completing 4 cycles of feeding and fasting, i.e. 28 days after study start. The timing of killing was decided based on previous trials in which hepatic damage was seen to be very high after four weeks in the steatosis group. Feed taken by the rats and weight of the animals were controlled at the end of the study. At the end of the study, all rats were anesthetized using an intraperitoneal injection of an overdose (45 mg/kg) of sodium pentobarbital.

Pathological evaluation
A histological study was performed following a midline laparotomy to remove the liver. Liver was weighed, and liver tissue samples taken at the time the rat was killed were immediately placed in 10% buffered formalin and subsequently embedded in paraffin. Hepatic index was obtained by dividing liver weight by rat weight × 100. Liver sections were stained with hematoxylin and eosin using standard techniques. Sections were viewed without knowing the treatment group to which each animal belonged. Biopsies were classified into four grades depending on fat accumulation using the Brunt et al [9] classification, assigning grade 0 when no fat was found in the liver, grade 1 when fat vacuoles were seen in less than 33% of hepatocytes, grade 2 when 33%–66% of hepatocytes were affected by fat vacuoles, and grade 3 when fat vacuoles where found in more than 66% of hepatocytes. The deposit of fat was classified in macrovesicular, microvesicular and mixed. Two experienced pathologists blinded to the experiment evaluated all samples. Agreement between both pathologists was determined.

Biochemical measurements
Laboratory parameters such as ALT, glucose, and albumin were measured using an automatic analyzer (Roche/Hitachi Modular Analytics, Roche Diagnostics, Mannheim, Germany) at 37°C.
Serum TNF-α levels was measured using ELISA kits (R&D Systems, Boston, MA-Catalog Number RTA00). TNF-α levels was expressed in pg/mL.

**Lipid peroxidation**
Malondialdehyde (MDA) was measurement in hepatic tissue. For hepatic malondialdehyde (MDA) determination, weigh 25 mg of tissue and add 250 μl of RIPA buffer with protease inhibitors. Sonicate for 15 seconds at 40 V over ice and centrifuge at 1.600 × g for 10 minutes at 4°C. We use the supernatant for analysis. MDA was quantified using the thiobarbituric acid reaction as described by Ohkawa [10]. MDA levels were measured using Cayman’s TBARS Assay Kit. MDA levels were expressed in μM.

**Oxidative stress**
Superoxide dismutase, catalase, glutathione peroxidase, and nitric oxide synthase levels as oxidant/antioxidant biochemical parameters were measurement in hepatic tissue. Levels were quantified using Cayman’s (Cayman Chemical Company, Ann Arbor – Michigan, USA) assay kit following the instructions of the manufacturer.

**Bacterial translocation determination**
Samples of mesenteric lymph nodes and portal and peripheral blood when available were collected under sterile conditions before rat death and cultured in MacConkey agar (Oxoid), Columbia sheep blood (Oxoid), and Esclin-Bile-Azide agar (Merck), and incubated at 37°C for 48 h. Bacterial translocation was defined as a positive culture of mesenteric lymph nodes. Systemic infections were defined as a positive culture of any of the remaining biological samples.

**Statistical analysis**
Data are expressed as the mean ± SD statistical analysis was performed with non-parametric Mann-Whitney test. Standard calculations were performed using SPSS version 16.0. Results were considered statistically significant at P < 0.05.

**Results**
Rat weight significantly increased in the control group (221 ± 10 g to 355 ± 16 g), remained similar in the group with fatty liver disease (222 ± 12 g to 226 ± 14 g), and decreased in the resveratrol group (218 ± 9 g to 201 ± 11 g). Hepatic index was 4.47 ± 0.63, 4.38 ± 0.34, and 3.9 ± 0.31 in the steatosis, resveratrol, and control groups respectively.

**Histological evaluation**
No fatty infiltration was seen in the control group (Figure 2). Mean fatty infiltration in the steatosis group was 3 (Table 1). Fat deposit in the steatosis group was classified as macrovesicular. Mean fatty infiltration in the resveratrol group was 1, and fat deposit was mixed. Fatty infiltra-
tion in the resveratrol group was significantly lower than in the steatosis group \( (P < 0.05) \). Inter-observer agreement was 0.84 and intra-observer agreement was 0.79.

**Laboratory findings**

ALT levels were 40 ± 11 IU/L in the control group, 34 ± 9 IU/L in the steatosis group, and 34 ± 11 IU/L in the resveratrol group \( (P < 0.05 \) between control group vs steatosis and resveratrol groups). Glucose levels were 230 ± 45 mg/dl in the control group, 162 ± 25 mg/dl in the steatosis group, and 145 ± 33 mg/dl in the resveratrol group. Statistically significant differences in glucose levels were seen between the control and steatosis groups and the resveratrol group \( (P < 0.05 \) between control group vs steatosis and resveratrol groups). Albumin levels were 38.1 ± 2.3 g/dl in the control group, 40.54 ± 1.87 g/dl in the steatosis group, and 41.1 ± 2.9 g/dl in the resveratrol group \( (P < 0.05 \) between control group vs steatosis and resveratrol groups).

**TNF-α and lipid peroxidation (MDA)**

Figure 3 shows that TNF-α levels were increased in the steatosis group as compared to the other two groups \( (P < 0.05) \). MDA was significantly elevated in the steatosis group as compared to the control group (μM). MDA liver levels were lower in the resveratrol group than in the steatosis group \( (P < 0.001) \).

**Oxidative stress**

The data in table 2 demonstrate that resveratrol administration significantly decreased the effects of the stress oxidative in the hepatic tissue.

**Bacterial translocation and systemic infections**

Cultures of samples of portal blood, peripheral blood, and perihepatic lymph nodes were negative in all three groups tested.

**Discussion**

NAFLD represents a wide spectrum of disorders, the hallmark of which is hepatic steatosis. NAFLD was considered a benign condition, but is now increasingly recognized as a major cause of liver-related morbidity and mortality. Insulin resistance is the basis for accumulation of free fatty acids and triglyceride storage in hepatocytes or steatosis. Oxidative stress from steatotic hepatocytes leads to lipid peroxidation, impaired mitochondrial and peroxisomal oxidation of fatty acids, and cytokine release [11]. Endotoxins and endotoxin-inducible cytokines, particularly TNF-α, are required for the pathogenesis of NAFLD in experimental animals. Therefore the TNF-α plays an important role in NAFLD [12,13].

In our study, hepatic steatosis was significantly decreased in rats treated with resveratrol. This effect was associated to a decreased TNF-α production. Different studies have shown that resveratrol decreases TNF-α production. We therefore think that the decreased liver damage in a model of liver steatosis could be related to its anti-TNF-α effect. Other studies [14-16] have shown a relation between NAFLD and TNF-α levels. Our study shows that TNF-α levels were increased in both the steatosis and resveratrol groups as compared to the control group, suggesting that TNF-α is an important factor in liver damage occurring in NAFLD. However, TNF-α levels were lower in the resveratrol group compared to the steatosis group.
Figure 3

TNF-α and MDA levels. A. TNF-α levels in different groups (pg/mL). TNF-α levels were lower in the resveratrol groups as compared to the control and steatosis groups. B. Levels of MDA in different groups (μM). MDA levels were lower in the resveratrol groups as compared to the steatosis group (*P < 0.05).
Bacterial translocation acting as a stimulus for TNF-α involved in the occurrence of bacterial translocation in hepatocytes, and represents the "first hit" in the pathogenesis of NAFLD [11]. Bacterial translocation from the intestinal lumen to mesenteric lymph nodes is considered to be one of the main events in the pathogenesis of spontaneous bacterial peritonitis and other infections in cirrhosis. TNF-α is involved in the occurrence of bacterial translocation in rats with cirrhosis [21]. We therefore considered whether bacterial translocation acting as a stimulus for TNF-α production occurred in our model. Cultures of samples of portal blood, peripheral blood, and perihepatic lymph nodes were negative in all three groups tested, which rules out this mechanism as responsible for TNF-α elevation.

Table 2: Changes of superoxide dismutase, catalase, glutation peroxidasa and nitric oxide synthase in each group.

|                          | Control     | Steatosis    | Resveratrol  |
|--------------------------|-------------|--------------|--------------|
| Superoxide dismutase (U/ml) | 2.74 ± 2.08 | 1.15 ± 2.1  | 3.1 ± 3.2*   |
| Catalase (nmol/min/ml)       | 3807 ± 315  | 284 ± 26     | 713 ± 50*    |
| Glutathione peroxidase (nmol/min/ml) | 449 ± 27  | 6.5 ± 3      | 406 ± 25*    |
| Nitric oxide synthase (uM)     | 1.9 ± 0.6   | 9.17 ± 0.9   | 4.19 ± 0.7*  |

*P < 0.05 vs steatosis group

There are many models of NAFLD liver injuries in animals [22,23]. In rats, cycles of feeding and fasting with hypertronic high calorie diets have been seen to induce fatty liver [8]. In this study, we used feeding and fasting cycles with a modified diet because it is a fast, easy procedure that results in pathological changes similar to those occurring in humans. In our model the deposit of fatty acids and triglyceride storage in hepatocytes is produced by insulin resistance [8,11]. Insulin resistance is the basis for accumulation of free fatty acids and triglyceride storage in hepatocytes, and represents the "first hit" in the pathogenesis of NAFLD [11]. Body mass significantly decreased with the high carbohydrate-fat free diet and dietary restriction. This may be due to a metabolic imbalance of carbohydrate, protein, and fat. However, hepatic index was higher in the group with steatosis as compared to the resveratrol and control groups. Such higher hepatic index occurred despite the increased rat weight in the steatosis group, which means that resveratrol acts by decreasing fat accumulation in the liver and fat weight, and therefore decreases hepatic index.

ALT is a relatively liver-specific aminotransferase. Elevation of ALT activity in serum is the result of leakage from damaged cells and therefore reflects hepatocyte damage. Elevated transaminase levels correlated strongly with NAFLD [2]. ALT levels were significantly lower in the resveratrol group as compared to control group (34 IU/L versus 40 IU/L) and similar to steatosis group levels. In the group treated with resveratrol, lower glucose levels and higher serum albumin levels as compared to untreated rats were also found. Studies have reported increases in serum TNF-α levels in humans with insulin resistance [24]. Hyperglycemia and insulin resistance are associated to the presence of NAFLD [2,25]. Changes in plasma levels of markers predicting for the onset of diabetes occurred with a high carbohydrate-fat free diet [25]. Glucose levels were decreased in the resveratrol group [26], as occurred in our study. Other studies have also noted that resveratrol improved insulin sensitivity, lowered plasma glucose, and increased mitochondrial capacity in obese mice [27]. Insulin resistance was not analyzed in our study.

High hepatic MDA levels were found in the steatosis group, in agreement with other studies [28]. Resveratrol improved MDA levels. Oxidative stress is believed to play an important role in pathogenesis of NAFLD. It is likely to be involved in disease progression from steatosis to steatohepatitis and potentially cirrhosis. It has been shown that chronic oxidative stress, generated through oxidation of cytotoxic free fatty acids, may lead to cytokine upregulation and depletion of hepatic antioxidant levels [29,30]. In addition, enhanced lipid peroxidation leads to the generation of by-products, such as MDA, which have been shown to further stimulate cytokine production. They are involved in hepatic stellate cell activation, fibrogenesis, and enhanced extracellular matrix protein deposition [28]. Resveratrol caused increased of hepatic antioxidant levels as superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver.

Fatty acid oxidation is an important source of reactive oxygen species in fatty livers. Some consequences of increased...
reactive oxygen species levels include an impaired protein stability, membrane destruction via lipid peroxidation, and release of proinflammatory cytokines (increased TNF-α levels) [31]. Reactive oxygen species may attack polyunsaturated fatty acids and initiate lipid peroxidation within the cell, which results in MDA formation. Oxidants may not only act as toxic substances, but also as second messengers (activation of transcription factor NF-kB) [32]. Resveratrol increases insulin sensitivity and insulin-like growth factor-1 levels (IGF-1) [28]. Resveratrol would also act by decreasing lipid peroxidation and reactive oxygen species release, thereby decreasing inflammatory response and liver lesions [33,34].

Recently, research suggests that other mechanisms the resveratrol improve in NAFLD are by the activation of AMP-activated protein kinase and the activation of SIRT1 [35–37].

**Conclusion**

In summary, our study shows that resveratrol decreases liver steatosis in rats and that its effect is mediated, at least partly, by TNF-α and antioxidant activities. In our model, bacterial translocation was not responsible for TNF-α elevation. Further studies are warranted to determine whether resveratrol decreases or prevents liver steatosis.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

LB, EH, MB, PA, and NG–U participated in study conception and design, manuscript preparation, and practical conduct of the study. CS collected and analyzed data and was involved in study conduct. AC and JA critically reviewed the manuscript. AG and BI carried out biochemical and microbiological tests. ML and EH performed the pathological examinations. All authors have read and approved the manuscript.

**Acknowledgements**

We thank Koro Berasarte for her technical assistance.

This work was supported by grants from the Plan Nacional I+D, Instituto de Salud Carlos III, Madrid, Spain (PI10/01730) and the Department of Health of the Basque Government (2005-111096 y 2007-02101). CIB-ERehd is funded by the Instituto de Salud Carlos III.

**References**

1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Am Intern Med 1997, 126(2):137-45.
2. Gholami PM, Fanchaum L, Machan JT, Charney DA, Kodly DP. Non-alcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102(2):399-408.
3. Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA: The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006, 16(10):1351-1358.
4. Shapiro H, Halpern Z, Bruck R: Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut 2007, 56(3):426-435.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kingonon AD, Metha RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297):218-220.
6. de la Lastra CA, Villegas I: Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms an clinical implications. Mal Nutr Res 2005, 49(5):405-430.
7. Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V, Bidaurrazaga J, Fernandez de Luco M, Gutierrez-Stampa MA, Larrazabal M, Hijona E, Sarasaqueta C, Echenique-Elizondo M, Arenas J: Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterology 2006, 6:35.
8. Delzenne NM, Hernaux NA, Taper HS: A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate-fat free diet. Biochemical and morphological analysis. J Hepatol 1997, 26(4):880-885.
9. Brunst EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
10. Okhawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95(2):351-358.
11. Paresi S, Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132(6):2191-2207.
12. James O, Day C: Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999, 353(915):1634-1636.
13. Day CP: Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver International 2006, 26(9):1021-1028.
14. Chu CJ, Lu RH, Wang SS, Chang FY, Wu SL, Lu CL, Chun BC, Chang CY, Wu MY, Lee SD: Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 2007, 54(79):2099-2102.
15. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elavinger H, Goldman Z, Chandoke V, Younossi ZM: Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27(5):412-421.
16. Manno M, Marcellini M, Giannone G, Nobili V: Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 127(6):954-960.
17. Seo YS, Kim JH, Jeo NY, Choi KM, Baik SH, Park JI, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008, 23(1):102-109.
18. Lieber CS, DeCarli LM, Leo MA, Mak KM, Ponomarenko A, Ren C, Wang X: Beneficial effects versus toxicity of medium-chin triacylglycerols in rats with NASH. J Hepatol 2008, 48(2):18-26.
19. Yalniz M, Bahceciooglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozcaner IH, Sahin K: Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007, 22(1):2009-14.
20. Barbuivo R, Milanski M, Bertolino MB, Saad MJ, Vellosos LA: Inflimixim reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007, 194(3):539-550.
21. Frances R, Chiva M, Sanchez E, Gonzalez-Navajas JM, Llovet T, Zapater P, Soriano G, Munoz C, Balanzo J, Perez-Maceo M, Song X, Giusti P, Such J: Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol 2007, 46(5):797-803.
22. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM: Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004, 79(3):502-509.
23. Koteish A, Diehl AM: Animal models of steatosis. Semin Liver Dis 2001, 21(1):89-104.
24. Shoelson SE, Herrero L, Naaz A: Obesity, inflammation and insulin resistance. Gastroenterology 2007, 132(6):2169-2180.
25. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakamura Y, Kaneko S: Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. *Gastroenterology* 2007, 132(1):282-293.

26. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein K, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puebsiderver P, Ingram KD, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006, 444(7117):337-342.

27. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bernis JE, Xie R, Disch JS, Ng PY, Nunes JI, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature* 2007, 450(7170):712-716.

28. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N: N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. *World J Gastroenterol* 2007, 13(38):5127-5132.

29. Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez Checa JC: Role of oxidative stress generated form the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. *Mut Pharmacol* 1995, 48(5):825-834.

30. Weltman MD, Farrell GC, Liddle C: Increased hepatocytes CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. *Gastroenterology* 1996, 111(6):1645-1653.

31. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 2004, 114(2):147-152.

32. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM, Thurman RG: NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. *J Clin Invest* 2000, 106(7):867-872.

33. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X: Resveratrol scavenges reactive oxygen species and affects radical-induced cellular responses. *Biochem Biophys Res Commun* 2003, 309(4):1017-1026.

34. Wu SL, Yu L, Meng KW, Ma ZH, Pan CE: Resveratrol prolongs allotransplant survival after liver transplantation in rats. *World J Gastroenterol* 2005, 11(30):4745-4749.

35. Deng XQ, Chen LL, Li NX: The expression of SIRT1 in non-alcoholic fatty liver disease induced by high fat diet in rats. *Liver Int* 2007, 27(5):708-715.

36. Pfluger PT, Herranz D, Velasco-Miguez S, Serrano M, Tschop MH: SIRT1 protects against high-fat diet-induced metabolic damage. *Proc Natl Acad Sci USA* 2008, 105(28):9793-9798.

37. Shang J, Chen L, Xiao F, Sun H, Ding H, Xiao H: Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. *Acta Pharmacol Sin* 2008, 29(6):698-706.

**Pre-publication history**

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-230X/8/40/prepub